[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-457233-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-457233-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","staged-approach-to-overcome-hyperbilirubinemia-tailored-chemotherapy-in-liver-metastases-a-case-report","Staged approach to overcome hyperbilirubinemia - tailored chemotherapy in liver metastases - a case report","","Staged approach to overcome hyperbilirubinemia using individualized chemotherapy was evaluated in a 73-year-old woman with poorly differentiated neuroendocrine carcinoma and extensive liver metastases complicated by severe hepatic dysfunction. Marked hyperbilirubinemia (total bilirubin 11.3 mg/dL) initially contraindicated standard systemic therapy. Palliative liver-directed radiation plus corticosteroids reduced bilirubin to 6.9 mg/dL, enabling weekly cisplatin, followed by cautious, dose-reduced gemcitabine as bilirubin further declined. Despite transient stabilization, imaging later showed progressive disease and transition to palliative care.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/staged-approach-to-overcome-hyperbilirubinemia-tailored-chemotherapy-in-liver-metastases-a-case-report/457233/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/staged-approach-to-overcome-hyperbilirubinemia-tailored-chemotherapy-in-liver-metastases-a-case-report/457233.png","ImageObject",300,407,{"name":42,"@type":43},"Bintang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why was standard systemic chemotherapy initially contraindicated in this case?","Question",{"text":63,"@type":64},"The patient had severe hyperbilirubinemia (total bilirubin 11.3 mg/dL) with marked hepatic dysfunction, which precluded use of standard systemic chemotherapy due to altered pharmacokinetics and safety concerns.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What staged interventions were used to enable chemotherapy?",{"text":68,"@type":64},"The approach started with palliative radiation therapy directed to the liver and corticosteroids to reduce hepatic inflammation and improve bile flow. After bilirubin levels fell, weekly cisplatin was initiated, followed by dose-reduced gemcitabine when further bilirubin reductions occurred.",{"name":70,"@type":61,"acceptedAnswer":71},"What was the overall outcome after initiating the tailored treatment sequence?",{"text":72,"@type":64},"Bilirubin decreased and systemic therapy was temporarily enabled, but follow-up imaging eventually demonstrated progressive disease with new metastases, leading to a transition to palliative care.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},457233,1790961653,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":4},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Staged approach to overcome hyperbilirubinemia: tailored chemotherapy in liver metastases-a case report  \nShadi Chamseddine1, Khalil Choucair2, Muhammad Wasif Saif2  \n1Department of Internal Medicine, Wayne State University, Detroit, MI, USA; 2Division of Hematology and Oncology, Department of Medicine, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA  \nContributions: (I) Conception and design: All authors; (II) Administrative support: MW Saif; (III) Provision of study materials or patients: MW Saif; (IV) Collection and assembly of data: S Chamseddine, K Choucair; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors;  \n(VII) Final approval of manuscript: All authors.  \nCorrespondence to: Muhammad Wasif Saif, MD. Division of Hematology and Oncology, Department of Medicine, Barbara Ann Karmanos Cancer  \nInstitute, 4100 John R St Detroit, MI 48201, USA. Email: [saifw@karmanos.org](saifw@karmanos.org).  \nBackground: Hyperbilirubinemia presents a significant challenge in the treatment of patients with hepatic dysfunction, particularly those with metastatic liver disease requiring chemotherapy. Many chemotherapeutic agents undergo hepatic metabolism and elimination, complicating treatment due to altered pharmacokinetics, increased toxicity risks, and the absence of standardized dose adjustments. Patients with severe hepatic impairment are frequently excluded from clinical trials, limiting available evidence on safe and effective treatment strategies for this group of patients. Emerging approaches, including corticosteroids, radiation therapy, and the use of non-hepatically metabolized agents, offer potential avenues for treatment, but clinical  \ndata remains limited.  \nCase Description: We report a case of a 73-year-old woman diagnosed with a poorly differentiated neuroendocrine carcinoma of unknown primary, presenting with extensive liver metastases and severe hepatic dysfunction. Upon admission, she exhibited significant hyperbilirubinemia (total bilirubin 11.3 mg/dL), precluding the use of standard systemic chemotherapy. A staged therapeutic approach was adopted, beginning with palliative radiation therapy to the liver and corticosteroid administration to reduce hepatic inflammation and improve bile flow. This intervention successfully lowered bilirubin levels to  \n6.9 mg/dL, enabling the initiation of weekly cisplatin, a renally excreted chemotherapeutic agent. Over time, further reductions in bilirubin permitted the introduction of gemcitabine, albeit at a reduced dose. Despite initial stabilization and a progressive decline in bilirubin, follow-up imaging showed progressive disease with  \nnew metastases, ultimately necessitating a transition to palliative care.  \nConclusions: This case highlights the potential role of a staged therapeutic strategy in managing severe hyperbilirubinemia in patients with advanced hepatic dysfunction. The use of corticosteroids and liverdirected radiation therapy facilitated chemotherapy initiation in a patient otherwise deemed ineligible for systemic therapy. While the patient ultimately experienced disease progression, this approach underscores the feasibility of individualized interventions to optimize treatment opportunities. This case demonstrateshow staged interventions can create a therapeutic window in patients typically ineligible for chemotherapy.  \nWhile initial bilirubin reduction allowed systemic therapy, disease progressed, highlighting the limits of current approaches and the need for further research into treatment sequencing and supportive strategies,  \nincluding liver-directed therapies and emerging systemic agents.  \nKeywords: Neuroendocrine tumor; hyperbilirubinemia; cisplatin; liver metastases; case report  \nSubmitted Feb 21, 2025. Accepted for publication Jun 17, 2025. Published online Dec 26, 2025.  \ndoi: 10.21037/jgo-2025-113  \nView this article at: [https://dx.doi.org/10.21037/jgo-2025-113](https://dx.doi.org/10.21037/jgo-2025-113)","cbCaiuhWB5fB92V2","https://ap.wps.com/l/cbCaiuhWB5fB92V2","pdf",341205,"English","# Background\n# Case Description\n# Conclusions\n# Introduction\n## Highlight Box\n### Key findings\n### What is known and what is new?","[{\"question\":\"Why was standard systemic chemotherapy initially contraindicated in this case?\",\"answer\":\"The patient had severe hyperbilirubinemia (total bilirubin 11.3 mg/dL) with marked hepatic dysfunction, which precluded use of standard systemic chemotherapy due to altered pharmacokinetics and safety concerns.\"},{\"question\":\"What staged interventions were used to enable chemotherapy?\",\"answer\":\"The approach started with palliative radiation therapy directed to the liver and corticosteroids to reduce hepatic inflammation and improve bile flow. After bilirubin levels fell, weekly cisplatin was initiated, followed by dose-reduced gemcitabine when further bilirubin reductions occurred.\"},{\"question\":\"What was the overall outcome after initiating the tailored treatment sequence?\",\"answer\":\"Bilirubin decreased and systemic therapy was temporarily enabled, but follow-up imaging eventually demonstrated progressive disease with new metastases, leading to a transition to palliative care.\"}]","Staged approach to overcome hyperbilirubinemia - tailored chemotherapy in liver metastases - a case report | PDF",1790748670]